Alnylam Pharmaceuticals, Inc.
ALNY
$219.78
$2.801.29%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.60% | 6.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.60% | 6.39% | |||
| Cost of Revenue | 41.36% | -21.14% | |||
| Gross Profit | 3.81% | 15.28% | |||
| SG&A Expenses | 7.87% | -0.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.91% | -6.92% | |||
| Operating Income | -13.85% | 103.95% | |||
| Income Before Tax | -19.78% | 37.56% | |||
| Income Tax Expenses | -15.00% | 161.95% | |||
| Earnings from Continuing Operations | -20.15% | 10.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.15% | 10.50% | |||
| EBIT | -13.85% | 103.95% | |||
| EBITDA | -13.06% | 94.31% | |||
| EPS Basic | -20.57% | 9.95% | |||
| Normalized Basic EPS | -20.20% | 80.78% | |||
| EPS Diluted | -19.78% | 10.29% | |||
| Normalized Diluted EPS | -19.82% | 79.12% | |||
| Average Basic Shares Outstanding | 0.54% | 0.50% | |||
| Average Diluted Shares Outstanding | 0.04% | 1.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||